Mois : mai 2019

Cannabis – Phytochemical, Pharmacological and Clinical Evidence, Scientific Symposium, University of Vienna, Austria, November 15, 2018

Cannabis – Phytochemical, Pharmacological and Clinical Evidence Scientific Symposium University of Vienna, Austria, November 15, 2018 Abstracts Organized by Herbal Medicinal Products Platform Austria (HMPPA) Society for Medicinal Plant and Natural Product Research (GA) Medical Cannabis and Cannabinoids, 2018, 1, 130–134 Published online: November 9, 2018 DOI: 10.1159/000494812 Breeding and Agronomical Techniques to Produce Medicinal Cannabis Gianpaolo Grassi CREA-CI, Research Centre for Cereal and Industrial Crops, Branch Station of Rovigo, Italy Cannabis Beyond the “Big Two” (THC and CBD)”: The Biological Potential of Minor Cannabinoids and of Non-Cannabinoid Constituents of Cannabis Giovanni Appendino1, Eduardo Muñoz2 1Dipartimento di Scienze del Farmaco, Largo Donegani 2, 28100 Novara, Italy; 2Maimonides Biomedical Research Institute of Córdoba. Avda Menendez Pidal s/n, 14004 Cordoba, [...]

Lire la suite

The Effect of Light Spectrum on the Morphology and Cannabinoid Content of Cannabis sativa L., Gianmaria Magagnini et al., 2018

The Effect of Light Spectrum on the Morphology and Cannabinoid Content of Cannabis sativa L. Gianmaria Magagnini, Gianpaolo Grassi, Stiina Kotiranta Medical Cannabis and Cannabinoids, 2018, 1, 19–27 DOI : 10.1159/000489030   Abstract Cannabis sativa L. flowers are the main source of Δ-9- tetrahydrocannabinol (THC) used in medicine. One of the most important growth factors in cannabis cultivation is light; light quality, light intensity, and photoperiod play a big role in a successful growth protocol. The aim of the present study was to examine the effect of 3 different light sources on morphology and cannabinoid production. Cannabis clones were grown under 3 different light spectra, namely [...]

Lire la suite

Acid Diethylamide (LSD) in the Treatment of Addictions : Historical Perspectives and Future Prospects, Mitchell B. Liester, 2014

Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects Mitchell B. Liester Current Drug Abuse Reviews, 2014, 7, 146-156 1874-4745/14 $58.00+.00 © 2014 Bentham Science Publishers   Abstract : Lysergic acid diethylamide (LSD) is a semisynthetic compound with strong psychoactive properties. Chemically related to serotonin, LSD was initially hypothesized to produce a psychosislike state. Later, LSD was reported to have benefits in the treatment of addictions. However, widespread indiscriminate use and reports of adverse affects resulted in the classification of LSD as an illicit drug with no accepted medical use. This article reviews LSD’s storied history from its discovery, to its use [...]

Lire la suite

Extractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses, Melissa M. Lewis-Bakker et al., 2019

Extractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses Melissa M. Lewis-Bakker, Yi Yang, Rupali Vyawahare, and Lakshmi P. Kotra Cannabis and Cannabinoid Research, 2019, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0067   Abstract Introduction : Phytocannabinoids, characteristic compounds produced by medical cannabis, interact with cannabinoid (CB) receptors (CB1 and CB2) as well as other receptor systems to exhibit their corresponding pharmacological effects. In their natural form, CBs such as D9-tetrahydrocannabinolic acid and cannabidiolic acid are inactive at these receptors, while their decarboxylated forms (D9 tetrahydrocannabinol and cannabidiol, respectively) are potent ligands at CB receptors. Thus, extraction and [...]

Lire la suite

CBD Gel Promising for Fragile X Syndrome, Megan Brooks, 2019

CBD Gel Promising for Fragile X Syndrome Megan Brooks Medscape, 2019 https://www.medscape.com/viewarticle/913267?nlid=129947_2052&src=WNL_mdplsnews_190524_mscpedit_psyc&uac=292598PZ&spon=12&impID=1974025&faf=1 SAN FRANSICO — A clear transdermal cannabidiol (CBD) gel (ZYN002, Zynerba Pharmaceuticals) improved emotional and behavioral symptoms experienced by children and adolescents with fragile X syndrome in a phase 2 open-label study, the company reports. ZYN002 met its primary endpoint, with patients demonstrating a 46% improvement in the total score on the Anxiety, Depression, and Mood Scale (ADAMS) at week 12 compared to baseline. ZYN002 also led to meaningful improvements in all measures of the Aberrant Behavior Checklist for Fragile X (ABC-FXS), which addresses the key symptoms of fragile X syndrome, including social avoidance, [...]

Lire la suite

Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland, Aleksi Mikael Markunpoika Hupli, 2018

Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland Aleksi Mikael Markunpoika Hupli Medical Cannabis and Cannabinoids, 2018, 1, 112–118 DOI: 10.1159/000495307 https://www.karger.com/Article/FullText/495307 Abstract : This paper presents a detailed patient case report of a male patient who was diagnosed in adulthood (aged 33) with attention deficit hyperactivity disorder (ADHD) and treated initially with immediate-release methylphenidate (Ritalin® 10 mg twice daily). After experiencing adverse effects from prolonged use of this medication and afterwards other medications that were prescribed as alternatives, the patient discovered that cannabinoid therapeutics (CT) had been experimented inside the EU area to treat patients with [...]

Lire la suite

Chemical and Biological Studies of Cannabis sativa Roots, Mostafa A. Elhendawy, et al., 2018

Chemical and Biological Studies of Cannabis sativa Roots Mostafa A. Elhendawy, Amira S. Wanas, Mohamed M. Radwan, Nabil A. Azzaz, ElShahat S. Toson, Mahmoud A. ElSohly Medical Cannabis and Cannabinoids, 2018, 1, 104–111 DOI: 10.1159/000495582 https://www.karger.com/Article/FullText/495582 Abstract : The chemical study of Cannabis sativa roots led to the isolation and identification of 10 compounds. Their chemical structures were unambiguously established on the basis of 1D and 2D NMR spectroscopy and mass spectrometry as friedelan- 3-one (1), epifriedelanol (2), β-sitosterol (3), ergost-5- en-3-ol (4), methyl hexadecanoate (5), pentadecanoic acid (6), 10E-hexadecenoic acid (7), 4-hydroxy 3-methoxybenzaldehyde (8), β-sitosterol-β-D-glucoside (9) and p-coumaroyltyramine (10). Compounds 5–9 were reported for the [...]

Lire la suite

Experimental Endozoochory of Cannabis sativa Achenes, John M. McPartland and Steve G. Naraine, 2018

Experimental Endozoochory of Cannabis sativa Achenes John M. McPartland and Steve G. Naraine Medical Cannabis and Cannabinoids, 2018, 1, 96–103 DOI: 10.1159/000492971 https://www.karger.com/Article/FullText/492971 Abstract : The mechanism by which Cannabis sativa dispersed from its center of origin remains an open question. The literature provides many hypotheses, which we review for the first time, but experiments are few. Darwin was interested in zoochory – the transport of plants by animals. He demonstrated endozoochory (transport of seeds via animal digestive systems) of C. sativa achenes (seeds) by carrier pigeons, but he did not quantify achene survival rates. We assessed mammalian endozoochory in a triplicate experiment: feeding C. sativa [...]

Lire la suite

Cannabinoid Hyperemesis, Joseph V. Pergolizzi Jr.,  Jo Ann LeQuang & John F. Bisney, 2018

Cannabinoid Hyperemesis Joseph V. Pergolizzi Jr.,  Jo Ann LeQuang, John F. Bisney Medical Cannabis and Cannabinoids, 2018, 1, 73–95 DOI: 10.1159/000494992 https://www.karger.com/Article/FullText/494992 Abstract : Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition in which a long-term cannabis user suffers an episode of intractable vomiting that may last days separated by longer asymptomatic periods of weeks or months. Cannabinoids are often utilized for their antiemetic properties, so CHS can be a puzzling condition, and the diagnosis of CHS may be disputed by patients. Unlike other cyclic vomiting syndromes, CHS can be relieved by hot showers or topical capsaicin. Abstinence from cannabinoids causes CHS to resolve, sometimes in [...]

Lire la suite

Medical Cannabis Safe, Effective for Neurologic Symptoms in the Elderly, Caroline Cassels, 2019

Medical Cannabis Safe, Effective for Neurologic Symptoms in the Elderly Caroline Cassels Medscape Medical News, 2019 https://www.medscape.com/viewarticle/912624_print PHILADELPHIA — Medical cannabis may be safe and effective in the treatment of a wide range of chronic symptoms related to various neurologic illnesses in elderly patients, early research suggests. In a preliminary study, investigators at the Dent Neurologic Institute in Buffalo, New York, found that the drug provided elderly patients relief from chronic pain, sleep disorders, and anxiety related to diseases such as amyotrophic lateral sclerosis, Parkinson disease, neuropathy, spinal cord damage, and multiple sclerosis. "Our findings show that medical marijuana is well-tolerated in people age 75 and [...]

Lire la suite